Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) saw some unusual options trading activity on Friday. Investors bought 33,310 call options on the stock. This is an increase of 73% compared to the average volume of 19,200 call options.
Viking Therapeutics Stock Performance
Shares of Viking Therapeutics stock opened at $70.47 on Friday. Viking Therapeutics has a fifty-two week low of $8.28 and a fifty-two week high of $99.41. The company has a market capitalization of $7.81 billion, a P/E ratio of -75.77 and a beta of 1.00. The company has a fifty day moving average of $59.08 and a 200 day moving average of $63.21.
Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last released its quarterly earnings data on Wednesday, July 24th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.06. During the same period in the prior year, the business posted ($0.19) earnings per share. Analysts forecast that Viking Therapeutics will post -1 EPS for the current year.
Insider Activity at Viking Therapeutics
Hedge Funds Weigh In On Viking Therapeutics
Several hedge funds have recently modified their holdings of the stock. Massmutual Trust Co. FSB ADV purchased a new position in shares of Viking Therapeutics during the first quarter valued at about $25,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Viking Therapeutics in the 2nd quarter valued at about $27,000. Lindbrook Capital LLC grew its position in Viking Therapeutics by 370.7% in the first quarter. Lindbrook Capital LLC now owns 353 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 278 shares in the last quarter. LifeSteps Financial Inc. bought a new stake in Viking Therapeutics during the first quarter worth approximately $37,000. Finally, Meeder Asset Management Inc. boosted its holdings in shares of Viking Therapeutics by 140.8% in the 2nd quarter. Meeder Asset Management Inc. now owns 802 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 469 shares during the period. Hedge funds and other institutional investors own 76.03% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on the company. StockNews.com raised Viking Therapeutics to a “sell” rating in a report on Wednesday, July 31st. JPMorgan Chase & Co. started coverage on Viking Therapeutics in a research note on Wednesday, September 11th. They set an “overweight” rating and a $80.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Viking Therapeutics in a research note on Thursday, July 25th. Truist Financial restated a “buy” rating and set a $120.00 target price on shares of Viking Therapeutics in a research report on Monday, June 17th. Finally, Maxim Group reaffirmed a “buy” rating and set a $120.00 target price on shares of Viking Therapeutics in a report on Tuesday, June 4th. One investment analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Viking Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $108.60.
Get Our Latest Stock Analysis on Viking Therapeutics
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Featured Stories
- Five stocks we like better than Viking Therapeutics
- What is the NASDAQ Stock Exchange?
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- What is the FTSE 100 index?
- MarketBeat Week in Review – 9/16 – 9/20
- Health Care Stocks Explained: Why You Might Want to Invest
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.